Cellular Biomedicine Group Inc. (NASDAQ:CBMG) spotted trading -26.17% off 52-week high price. On the other end, the stock has been noted 27.69% away from the low price over the last 52-weeks. The stock changed 0.14% to recent value of $14.02. The stock transacted 122829 shares during most recent day however it has an average volume of 68.26K shares. The company has 20.47M of outstanding shares and 10.76M shares were floated in the market.

On May 06, 2020, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, released business highlights and financial results for the first quarter of 2020.

We currently have six clinical assets in development. In Q1, China’s National Medical Products Administration (NMPA) accepted our Investigational New Drug (IND) application for B-cell maturation antigen (BCMA) Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM). Although early in the study, we are guardedly optimistic about the preliminary data of the 19 infused patients with only one patient being observed to have grade 3 cytokine release syndrome (CRS). We are excited to continue the development of this program and believe that our competitive advantages may be partially attributable to our proprietary manufacturing process with reduced vein-to-vein times. We are also conducting an Investigator-Initiated Trial (IIT) on our anti-CD19/CD20 BiCAR-T in non-Hodgkin’s lymphoma (NHL) in China and are seeing promising early data, said Tony (Bizuo) Liu, the Company’s Chief Executive Officer.

Mr. Liu added, Together with our new Rockville, Maryland facility coming online in the latter part of the year, which will support the early phases of our U.S. clinical trials, and observation of the promising data in our China study, we are taking small steps to explore feasibility of a U.S. clinical trial for anti-CD19/CD20 BiCAR-T for non-Hodgkin’s lymphoma (NHL) as well as the tumor infiltrating lymphocytes (TIL) clinical trial for Non-Small-Cell Lung Cancer (NSCLC).

Its earnings per share (EPS) expected to touch remained -19.90% for this year. CBMG has a gross margin of 81.60%.

According to the most recent quarter its current ratio was 1.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of -5.48% from the mean of 20 days, -6.47% from mean of 50 days SMA and performed -9.23% from mean of 200 days price. Company’s performance for the week was -4.11%, -9.68% for month and YTD performance remained -13.79%.